ACM
RXRX icon

Aster Capital Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Aster Capital Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.21K Buy
1,419
+809
+133% +$2.69K ﹤0.01% 720
2026
Q1 		$3.23K Sell
610
-2,850
-82% -$11K ﹤0.01% 721
2025
Q4 		$14.2K Buy
+3,460
New +$17.1K 0.01% 692
2025
Q2 		– Sell
-2,377
Closed -$17.9K – 1503
2025
Q1 		$17.9K Buy
2,377
+1,114
+88% +$8.12K ﹤0.01% 1002
2024
Q4 		$8.54K Buy
+1,263
New +$8.49K ﹤0.01% 790

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Aster Capital Management's RXRX Position: Q2 2026 in Review

Aster Capital Management increased its Recursion Pharmaceuticals (RXRX) stake by 133% in Q2 2026, buying an estimated $2.69K and bringing the position to 1,419 shares worth $5.21K. The position accounts for ﹤0.01% of the portfolio, ranked #720.

Aster Capital Management first reported a position in RXRX in Q4 2024 and has held it in 5 quarters since. The position peaked at $17.9K in Q1 2025. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Aster Capital Management held 1,419 shares of Recursion Pharmaceuticals worth $5.21K as of Q2 2026.
  • Aster Capital Management bought 809 Recursion Pharmaceuticals shares in Q2 2026, an estimated $2.69K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Aster Capital Management's portfolio in Q2 2026, its #720 holding.
  • Aster Capital Management first reported a position in Recursion Pharmaceuticals in Q4 2024 and has held it in 5 quarters since.
  • Aster Capital Management's Recursion Pharmaceuticals position peaked at $17.9K in Q1 2025.
  • 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Aster Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.